

## CURRICULUM VITAE

**NAME :** Richard J. Barth, Jr., M.D.

**HOME ADDRESS:** 9 Orchard Hill  
Hanover, New Hampshire 03756  
(603) 643-0105

**OFFICE ADDRESS:** Section of General Surgery  
Department of Surgery  
Dartmouth-Hitchcock Medical Center  
Lebanon, New Hampshire 03756  
(603) 650-7903

**DATE OF BIRTH:** July 7, 1959  
**PLACE OF BIRTH:** Manhasset, New York

**EDUCATION:** Harvard Medical School 1985 (M.D.)  
Boston, MA

Princeton University 1981 (A.B.)  
Princeton, NJ  
Summa cum laude

**POSTDOCTORAL TRAINING:** Surgery Resident 1991-1992  
New England Deaconess  
Harvard Surgical Service

Surgical Oncology Fellow 1988-1990  
National Cancer Institute

Surgery Resident 1985-1988  
New England Deaconess  
Harvard Surgical Service

**LICENSURE AND CERTIFICATION:** New Hampshire (8817) 1992  
Massachusetts (60577) 1987

Diplomate,  
National Board of Medical Examiners 1986

Certified, American Board of Surgery #39469 1994

**ACADEMIC/HOSPITAL  
APPOINTMENTS:**

Assistant Professor of Surgery Dartmouth Medical School Hanover, New Hampshire	1993-8
Associate Professor of Surgery Dartmouth Medical School Hanover, New Hampshire	1999-2007
Clinical Staff Mary Hitchcock Memorial Hospital Lebanon, New Hampshire	1993-2007

**HONORS AND  
AWARDS:**

<u>Princeton University:</u> Academic Excellence Award, Biochemical Sciences Leopold Schepp Foundation Scholarship Class of 1883 English Prize Freshman First Honor Prize (awarded to the student with the highest GPA in the class after Freshman year)	1981
<u>Harvard Medical School:</u> Administrative Chief Resident Deaconess-Harvard Surgical Service	1992
<u>Dartmouth Medical School:</u> American Cancer Society Career Development Award	1995
Surgery Chief Residents' Award for Teaching Excellence	1998
Alma Hass Milham Award (Awarded by the clinical faculty of Dartmouth Medical School for clinical excellence and compassion in patient care)	1998
Alpha Omega Alpha (Elected by Dartmouth Medical students for strength of character, academic accomplishment and dedication to teaching)	1999
Society of University Surgeons	1999

Chairman's Award (Awarded by the surgical faculty of Dartmouth Medical School for combining excellence in clinical care, research and teaching)	2000
The Arthur Naitove Distinguished Teaching Award (Awarded by the residents in the Dept. of Surgery)	2001
The Dartmouth-Mosenthal Surgical Fellowship (Awarded by Dartmouth Medical School students for contributions to DMS as a surgeon, teacher, scholar and friend.)	2002
Finalist, Leonard Tow Humanism in Medicine Award	2005, 2006
Mentor to Sarah Greer, MD, First Place Resident Presentation Award, New England Surgery Society Annual Meeting	2005
Dartmouth Medical School Excellence in Teaching Award (from medical students in the core surgery clerkship)	2006
Leading Physician, Breast Surgery, NH Magazine	2008

**ADMINISTRATIVE  
RESPONSIBILITIES:**

National/Regional:

New England Surgical Society, Program Committee	2003-7
New England Cancer Society, Executive Committee	2000-3
Cancer and Leukemia Group B, Surgery Committee	1998-2001

Norris Cotton Cancer Center:

Co-Director, Immunology and Cancer Immunotherapy Research Program	2002-7
Chairman, Clinical Cancer Care Committee	2002-4

Clinical Cancer Care Committee	1999-2005
Executive Committee	2002-7
Director, Gastrointestinal Oncology Program	1996-2004
Clinical Cancer Research Committee	1993-2002

Department of Surgery

Chief, Section of General Surgery	2003-7
Chief, Division of Surgical Oncology	2002-7
Residency Advisory Committee	1994-2000
Surgery Advisory Committee on Education	1995-9

**PROFESSIONAL  
SOCIETIES:**

Aesculapian Club  
Alpha Omega Alpha  
American Association for the Advancement of Science  
American Association for Cancer Research  
Association for Surgical Education  
Faculty of American College of Surgeons  
International Society for the Biological Therapy of Cancer  
New England Surgical Society  
New Hampshire Medical Society  
Phi Beta Kappa  
Sigma Xi  
Society of Surgical Oncology  
Society of University Surgeons

**RESEARCH FUNDING:**

American Cancer Society Institutional Research  
Grant , IRG 1571 . "Effects of interleukin-10 on the  
murine anti-tumor immune response". Principal investigator.  
\$18,300, 6/93 - 6/94

Hitchcock Foundation Research Grant 250-186.  
"Cytokine gene expression in human colon and breast  
cancer in situ". Principal investigator. \$6500, 6/94 - 6/95

American Cancer Society Career Development  
Award. "Cytokine production in situ by lymphocytes  
in human malignancies". Principal investigator. \$90,000,  
7/95 - 6/98

Association for Surgical Education Grant. "Can  
behavioral intervention improve communication skills  
in surgical residents". Principal investigator. \$3500,  
11/95- 11/96

Norris Cotton Cancer Center Interactive Pilot Project Grant.  
"Evaluation of immune deficits in freshly isolated tumor  
infiltrating lymphocytes". Co-investigator. \$25,000, 6/96 -  
6/97.

"A prospective study of adjuvant radiation therapy after  
breast conserving resection of borderline and malignant  
phyllodes tumors", Principal investigator, 2/98-present,  
unfunded.

Hitchcock Foundation research grant, "Studies of the route of  
administration of dendritic cell vaccines", Mentor to Laura  
Lambert, MD, \$15,000, 7/99-7/00.

1R29CA776612-01 , "Mechanisms underlying CD40L's role in  
tumor immunity". Principal investigator. \$350,000,  
7/98-7/2004.

P20 RR16437, Project 5 "A trial of a CD40 activated dendritic  
cell vaccine in patients with resected colorectal cancer".  
Principal Investigator. \$168,000 per year, 9/30/01- 12/31/04.

2 PO1 CA080139-06A1 (Paulsen, Keith, PI) Alternative Breast  
Cancer Imaging Modalities, Co-investigator, 10% effort, 9/05-  
present

2 P30 CA023108-27 (Israel, Mark A., P.I.) Norris Cotton Cancer  
Center Support Grant 10% effort, \$1,828,696 Total Award. Period: 12/1/2003-  
11/30/2008

Norris Cotton Cancer Center Research Grant, "A pilot study of US  
guided cryoablation of small unifocal invasive ductal breast cancer using MRI to

evaluate tumor viability and immunologic assays to identify and characterize a cryoablation induced immune response".

Co-investigator, \$20,000, 5/07-5/08.

Sanarus Corp Research Grant, A pilot study of US guided cryoablation of small unifocal invasive ductal breast cancer using MRI to evaluate tumor viability and immunologic assays to identify and characterize a cryoablation induced immune response".

Co-investigator, \$10,000, 5/07-5/08.

## **FEDERAL RESEARCH GRANT REVIEW SERVICE:**

Cancer Therapy Evaluation Program (CTEP) Concept Review Committee	2005
NCI Program Project Grant Review team member, Mt Sinai School of Medicine	2003
NCI Program Project Grant Review team member, Univ. of Michigan	2003 + 6

## **TEACHING EXPERIENCE:**

Research trainees:	
John Gorechlad, MD	2007
Elsa Valsdottir, MD	2003-4
Cheryl Guyre, PhD	2000-1
Christopher Alessi, MD	2000-1
Glen Gibson, MD	1999-2000
Laura Lambert, MD	1998-2000
Thomas Schwaab, BS	1998
James Feeney, BS	1997
Patrick Ting, MD	1996-7
Teresa Martuscello, BS	1995
Benjamin Camp, MD	1994-5
Sonya Dyhrman, BS	1993-4

Certifying Examiner, American Board of Surgery 2008

Director, Surgery Resident Teaching Course 1993-2007

Surgical Oncology Rounds, preceptor,  
weekly surgery resident conference 1995-2002

Preceptor, Dartmouth Medical School (DMS)

Core Clerkship in Surgery	1993-2007
Preceptor, DMS Special Elective in Surgical Oncology	1994-5
Lecturer, DMS Principles of Surgery: Surgical Anatomy	1994-6
Lecturer, DMS Oncology course, Breast cancer	1999-2001
Lecturer, DMS Scientific Basis of Medicine GI block: Appendicitis, Diverticular Disease, Pancreatic cancer	1996-2007

**EDITORIAL BOARDS:**

Journal of Immunotherapy	1997-2007
Annals of Surgical Oncology	2003-7
Ad hoc reviewer: J. Clin. Oncology, The Cancer Journal, Cancer Research, Annals of Surgical Oncology, Int. J. Cancer, Surgery	

## PUBLICATIONS

### Journal Articles:

1. **Barth RJ**. The health effects of diesel emissions. *The Princeton Journal of Arts and Sciences* 1982, 77-97.
2. **Barth RJ**, Mule JJ, Bock S, Rosenberg SA. Generation of rapidly proliferating tumor infiltrating lymphocytes with cytolytic specificity and therapeutic efficacy in mice. *Surg Forum* 1989, 431-432.
3. **Barth RJ**, Bock S, Mule JJ, Rosenberg SA. Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes. *J Immunol* 1990, 144:1531-1537.
4. **Barth RJ**, Mule JJ, Speiss PJ, Rosenberg SA. Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor infiltrating lymphocytes. *J Exp Med* 1991, 173:647-658.
5. **Barth RJ**, Danforth DN, Venzon DJ, et al. Level of axillary involvement by lymph node metastases in breast cancer is not an independent predictor of survival. *Arch Surg* 1991, 126:574-577.
6. **Barth RJ**, Venzon DJ, Baker AR. The prognosis of melanoma patients with metastases to two or more lymph node areas. *Ann Surg* 1991, 214:125-130.
7. **Barth RJ**, Baker AR. Pedunculated lipoma of the thigh. *Surg Rounds* 1991, 14:449-450.
8. **Barth RJ**, Mule JJ, Asher AL, Sanda MG, Rosenberg SA. Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes: tumor specific secretion of interferon gamma and tumor necrosis factor. *J Immunol Methods*, 1991, 140:269-279.
9. Restifo N, Esquivel F, Asher A, Stotter H, **Barth RJ**, et al. Defective presentation of endogenous antigens by a murine sarcoma: implications for the failure of an anti-tumor immune response. *J Immunol* 1991, 147:1453-1459.
10. Kaiser CW, McAuliffe JD, **Barth RJ**, Lynch JD. Hypoprothrombinemia and hemorrhage in a surgical patient treated with Cefotetan. *Arch Surg* 1991, 126:524-525.
11. **Barth RJ**, Merino MJ, Solomon D, Yang JC, Baker AR. A prospective study of the value of core needle biopsy and fine needle aspiration in the diagnosis of soft tissue masses. *Surgery* 1992, 112:536-543.
12. Valone, F, Kaufman, P, Guyre, P, Lewis, L, Memoli, V, Ernstoff, M, Wells, W,



- Barth, R**, Deo, Y, Fisher, J. Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that over-expresses HER-2/neu. *J Hematother* 1995, 4:471-5.
13. Camp BJ, Dyhrman ST, Memoli VA, Mott LA and **Barth RJ**. In situ cytokine production by breast cancer tumor infiltrating lymphocytes. *Annals of Surgical Oncology* 1996, 3:176-84.
  14. **Barth RJ**, Coppola MA and Green WR. The in vivo effects of locally secreted IL-10 on the murine anti-tumor immune response. *Annals of Surgical Oncology* 1996, 3: 381-6.
  15. **Barth RJ**, Camp BJ, Martuscello T, Mott LA and Memoli VA. The cytokine microenvironment of human colon cancer: lymphocyte production of TNF and IL-4 predicts improved survival. *Cancer* 1996, 78:1168-78.
  16. Steinhorsson G, Perry A and **Barth RJ**. Cutaneous fibrous histiocytoma with osteoclast-like giant cells. *Annals of Plastic Surgery* 1996, 37:217-9.
  17. **Barth, RJ**, Rowland-Morin, PA, Mott, LA, and Burchard, KW. Communication effectiveness training improves surgical resident teaching ability. *J. Amer. Coll. Surgeons* 1997; 185: 516-19.
  18. Mackey M, Gunn J, Ting P, Kikutani H, Dranoff G, Noelle R and **Barth RJ**. Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154. *Cancer Research* 1997, 57:2569-74.
  19. **Barth RJ**, Burchard K, Tosteson A, Sutton J, Colacchio T, Henriques H, Howard R, Steadman S. Short-term outcome after mesh or Shouldice herniorrhaphy: a randomized, prospective study. *Surgery* 1998, 123:121-6.
  20. Mackey M, Noelle R, **Barth RJ**. The role of CD40/CD154 interactions in the priming, differentiation and effector function of helper and cytolytic T cells. *J Leukocyte Biology* 1998, 63: 418-28.
  21. Mackey M, Gunn J, Maliszewski C, Kikutani H, Noelle R, **Barth RJ**. Dendritic cells require maturation via CD40 in vivo to generate protective anti-tumor immunity, *J. Immunology* 1998, 161:2094-8.
  22. **Barth RJ**. Histologic features predict local recurrence after breast conserving therapy of phyllodes tumors, *Breast Cancer Research and Treatment* 1999, 57:291-5.
  23. **Barth RJ**, Schwaab T. Influence of the cytokine microenvironment on dendritic cell infiltration in colon cancer. *Surg Forum* 1999, 302-4.
  24. Lambert L, Colacchio T, **Barth RJ**. Interval hepatic resection of colorectal metastases improves patient selection, *Archives of Surgery* 2000, 135:473-80.

25. Lambert L, Gibson G, **Barth RJ**. Intranodal immunization with a dendritic cell tumor vaccine is More effective than subcutaneous or intravenous routes, *Surg Forum* 2000.
26. Schwaab T, Weiss J, Schned A, **Barth RJ**. Influence of the cytokine microenvironment on dendritic cell infiltration in colon cancer, *J Immunotherapy* 2001, 24: 130-7.
27. Lambert L, Gibson G, Maloney M, Durell B, Noelle R, **Barth RJ**. Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective anti-tumor immunity, *Cancer Res* 2001, 61: 641-6.
28. Lambert L, Gibson G, Maloney M, **Barth RJ**. Equipotent generation of protective anti-tumor immunity by various methods of dendritic cell loading with whole cell tumor antigens, *J Immunotherapy* 2001, 24: 232-6.
29. Pipas J, Mitchell S, **Barth RJ**, Vera-Gimon R, Rathmann J, Meyer L, Wagman R, Lewis L, McDonnell C, Colacchio T, Perez R. A phase I study of twice weekly Gemcitabine and concomitant external beam radiation therapy in patients with adenocarcinoma of the pancreas, *Int. J. Rad Onc Biol Physics* 2001, 50: 1317-22.
30. Gibson G, Lesnikoski B, Yoo J, Mott L, Cady B, **Barth RJ**. A comparison of ink directed and traditional whole cavity re-excision for breast lumpectomy specimens with positive margins, *Annals of Surgical Oncology* 2001, 8:693-704.
31. Guyre C, Fisher J, Waugh M, Wallace P, Tretter C, Ernstoff M, **Barth RJ**. Advantages of hydrophobic culture bags over flasks for the generation of monocyte-derived dendritic cells for clinical applications, *J. Immunological Methods* 2002, 262:85-94.
32. Frleta D, Lin J, Quezada S, Wade T, **Barth R**, Noelle R, Wade W. Differential maturation of in vitro and in vivo CD40-matured dendritic cells, *J. Immunotherapy* 2003, 26: 72-84.
33. Killoran T, Wells W, **Barth RJ**, Goodwin D. Leiomyosarcoma of the popliteal vein, *Skeletal Radiology* 2003, 32:174-8.
34. Ahonen C, Doxsee C, McGurran S, Riter T, Wade, W, **Barth RJ**, Vasilakos J, Noelle R and Kedl R. Adjuvant effects of combined TLR and CD40 Triggering on cell mediated immunity are dependent on type 1 IFN, *J Exp Med* 2004, 199: 775-784.
35. **Barth RJ**, Gibson G, Carney P, Mott L, Becher R, Poplack S. Detection of breast cancer by screening mammography allows patients to be treated with less toxic therapy, *Am J Roentgenology* 2005, 184: 324-9.

36. Tretter C, Schwaab T, **Barth RJ**, Perry A, Philips D, Fisher J, Waugh M, Mellinger D, Crocenzi T, Crosby N, Truman D, Cole B, Spencer S, Ernstoff M. A Pilot study of the effects on T cell precursor frequency and clinical outcomes in patients with high-risk and metastatic melanoma treated with autologous tumor vaccine and GM-CSF, submitted for publication.
37. Pipas, JM, **Barth RJ**, Zaki B, Tsapakos M, Bettmann M, Cates J, Suriawinata A, Ripple G, Sutton J, Gordon S, McDonnell C, Perez R, Redfield N, Meyer L, Marshal J, Cole B, Colacchio T. Docetaxel/gencitabine followed by Gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma, *Ann Surg Onc* 2005, 12: 1-10.
38. Siegel A, Alvarado M, **Barth RJ, Jr.**, Brady M, Lewis J. Parameters in the prediction of the sensitivity of parathyroid scanning. *Clin Nucl Med* 2006; 31:679-82.
39. Ernstoff M, Crocenzi T, Seigne J, Crosby N, Cole B, Fisher J, Uhlenhake J, Mellinger D, Foster C, Farnham C, Mackay K, Szczepiorkowski Z, Webber S, Schned A, Harris R, Noelle R, **Barth R**, Heaney J. Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yang, *Clinical Cancer Research* 2007. 13: 733s-740s.
40. Greer S, Pipas J, Sutton J, Zaki B, Tsapakos M, Colacchio T, Gibson J, Wiener, D, Ripple, G, **Barth RJ**. Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma. *J Am Coll Surg* 2008, 206: 451-7.
41. Gorechlad J, McCabe E, Higgins J, Likosky D, Lewis P, Rosenkranz K, **Barth RJ**. Screening for Recurrences in Patients Treated with Breast Conserving Surgery: Is there a Role for MRI? *Annals of Surgical Oncology* 2008, 15:1703-9.
42. Thomas Schwaab, Todd S. Crocenzi, John D. Seigne, Nancy A. Crosby, Bernard F. Cole, Jan L. Fisher, Jill C. Uhlenhake, Diane Mellinger, Cathy Foster, Cheryl Carlson, Kathleen Mackay, Zbigniew M. Szczepiorkowski, Susan M. Webber, Alan R. Schned, Robert D. Harris, **Richard J. Barth, Jr.** Adrian Schwarzer, John A. Heaney, Randolph J. Noelle, and Marc S. Ernstoff. Autologous Intranodal Dendritic Cell Vaccine with Aldesleukin and Inteferon $\alpha$  Therapy in Metastatic Renal Cell Carcinoma Patients, submitted for publication.
43. Ketcham S, Crocenzi T, Meehan K, Hill J, Cole B, Uhlenhake J, Fisher J, Crosby N, Noelle R, Usherwood E, **Barth R**, Ahonen C, Fuse S, Ernstoff M. Lymphodepletion with high-dose IL-2 and GM-CSF in metastatic melanoma patients: a preliminary report, submitted for publication.
44. Szafranska A, Doleshal M, Edmunds H, Gordon S, Luttges J, Mundingv J, **Barth R**, Gutmann E, Siriwainata A, Pipas M, Tannapfel A, Korc M, Hahn S, Labourier E, Tsongalis G. Analysis of microRNAs in pancreatic fine needle aspirates can classify benign and malignant tissues, *Clinical Chemistry* 2008, 54: 1716-24.

45. Collins E, Moore C, Clay K, Kearing S, O'Connor A, Llewellyn-Thomas H, **Barth R**, Sepucha K. Can women with early stage breast cancer make an informed decision for mastectomy?, in press, J of Clinical Oncology.

### **Book Chapters:**

1. **Barth RJ**. Lymphocyte cytokine secretion in response to tumors. In: Chang AE and Shu S, ed. Immunotherapy of Cancer with Sensitized T Lymphocytes. R. G. Landes Co., Austin, TX., 1994, p. 79 - 89.
2. **Barth RJ** and Mulé JJ. Cytokine gene transfer into tumor cells: animal models. In: Moen R and Brenner M , ed. Gene Therapy in Cancer. Marcel Dekker, Inc., NY, NY, 1996, p. 73- 93.
3. **Barth RJ** and Mule, JJ. Interleukin-2: Preclinical trials. In: Rosenberg SA, ed. Biologic Therapy of Cancer: Principles and Practice. Lippincott Williams and Wilkins, Phil. PA, 2000, p. 19-31.

### **PRESENTATIONS AT NATIONAL MEETINGS**

1. **Barth RJ**, Mule J, Bock S, and Rosenberg S. Generation of rapidly proliferating tumor infiltrating lymphocytes with cytolytic specificity and therapeutic efficacy in mice. Presented: Surgical Forum, American College of Surgeons, 1989.
2. **Barth RJ**, Mule J, and Rosenberg S. TIL with in vitro cytolytic specificity are specifically therapeutic in vivo. Presented: American Association of Cancer Research, 1990.
3. **Barth RJ** and Coppola, M. Lack of an immunosuppressive effect of IL-10 on the murine anti-tumor immune response. Presented: Society of Biologic Therapy, 1994.
4. Camp B, Memoli V and **Barth RJ**. In situ cytokine secretion by breast cancer TIL. Presented: Society of Surgical Oncology, 1995.
5. **Barth RJ** and Coppola, M. Lack of an immunosuppressive effect of IL-10 on the murine anti-tumor immune response. Presented: Society of Surgical Oncology, 1995.
6. **Barth RJ** Cytokine production in situ by lymphocytes infiltrating human tumors.

Presented: Frederick Collier Society meeting, 1995.

7. Kaufman P, Valone F, Gerke G, Guyre P, Memoli V, **Barth R**, Phipps K, Lewis L, Deo Y and Fanger M. Immunological stimulation of bispecific antibody (BsAb) MDX-210 (Anti-FcγR1 X Anti-HER-2/neu) in patients with breast or ovarian cancer that overexpress HER-2/neu is schedule dependent. Presented: American Society of Clinical Oncology, 1995.
8. **Barth RJ** and Memoli,V. TNF and IL-4 produced in situ by colon cancer tumor infiltrating lymphocytes predicts survival. Presented: Society of Surgical Oncology, 1996.
9. **Barth RJ**. Cytokine production in situ by lymphocytes infiltrating human tumors. Presented: Eastern Surgical Society, 1996.
10. Anthony S, Ihnat M, Ernstoff M, Kaufman P, Lewis L, **Barth R**, Memoli V, Dain B, Arvizu C, MacKay K, Daly-Finn L, and Hamilton J. Suppression in expression of P-glycoprotein and other proteins associated with multidrug resistance (MDR) by mitomycin C in metastatic breast cancer patients: preliminary results from a pilot clinical trial. Presented: American Association for Cancer Research, 1996.
11. **Barth, RJ**, Burchard, K, Sutton, J, Tosteson, A, Colacchio, T, Henriques, H, Howard, R, and Steadman, S. Short-term outcomes following mesh or Shouldice herniorrhaphy: a randomized, prospective study. Presented: New England Surgical Society, 1996.
12. Kaufman PK, Lewis LD, **Barth RJ**, et. al. Bispecific antibody 520C9 X 22 and interferon gamma is an immunologically active treatment for patients with metastatic adenocarcinomas that overexpress Her-2/neu. Presented: San Antonio Breast Cancer Symposium, 1996.
13. Mackarem, G, Roche, C, **Barth, R**, Ting, P, Hughes, K. Does mammography benefit women in their forties? Presented: New England Cancer Society, 1996.
14. Kaufman P, GuyreP, **Barth R**, Lewis L, Memoli V, Curnow R, Deo Y, Harris R, Valone F, Wallace P, Wells W, Schned A, Fisher J, Waugh M, Phipps K, MacKay K, Fanger M, Ernstoff M. Phase I trial of interferon gamma and MDX 210 inpatients with metastatic carcinomas that overexpress her-2/neu. American Society of Clinical Oncology 1997.
15. **Barth, RJ**, Mackey, M, Gunn, J, Ting, P, Noelle, R. CD40/CD40L interactions have a critical role in T cell priming induced by tumor vaccines. Presented: American Association for Cancer Research, 1997.
16. **Barth, RJ**, Rowland-Morin, PA, Mott, LA, Burchard. KW. Communication effectiveness training improves surgical resident teaching ability. Presented: Association for Surgical Education, 1997.

17. **Barth, RJ**, Mackey M, Gunn J, Noelle R. Dendritic cells require activation via CD40 in vivo to generate protective anti-tumor immunity, Presented: Society of Surgical Oncology 1998.
18. Lambert L, Colacchio T, **Barth RJ**. Interval hepatic resection of colorectal metastases improves patient selection. Presented: New England Surgical Society 1999.
19. **Barth RJ** and Schwab T, Influence of the cytokine microenvironment on dendritic cell infiltration in colorectal cancer. Presented: American College of Surgeons Surgical Forum 1999.
20. Kaufman P, Lewis L, Nervi A, **Barth R**, Cole B, Anthony S, Hermann D, Ernstoff M, Hamilton J. Phase I trial of mitomycin c down regulation of multidrug resistance proteins and mitomycin c and paclitaxel combination therapy. Proc Am. Soc. Clin. Oncology 1999.
21. Tretter C, Schwaab T, Heaney J, **Barth R**, Perry A, Cole B, Schned A, Phillips D, Fisher J, Waugh M, Ernstoff M. Increase in T cell precursor frequency in patients with renal cell carcinoma and melanoma treated with autologous tumor vaccine plus GM-CSF. ASCO, 2000.
22. **Barth RJ**. Discussant: Universal helper peptides augment dendritic cell based anti-tumor vaccines, New England Surgical Society, 2000.
23. Lambert L, Gibson G, **Barth RJ**. Intranodal immunization with a dendritic cell tumor vaccine is more effective than subcutaneous or intravenous routes. Presented: American College of Surgeons Surgical Forum 2000.
24. **Barth RJ**, Mitchell S, Wells W. A prospective study of adjuvant radiation therapy after resection of borderline and malignant phyllodes tumors: interim report. Presented: New England Cancer Society, 2000.
25. Gibson G, Lesnikoski B, Yoo J, Cady B, **Barth RJ**. A comparison of ink directed and whole cavity re-excision for breast lumpectomy specimens with positive margins. Presented: Society of Surgical Oncology, 2001.
26. **Barth RJ**. Treatment of patients with metastatic colon cancer with a dendritic cell vaccine. Presented: New England Cancer Society, 2002.
27. Pipas, J.M., **Barth RJ**, Zaki B, Colacchio T, Gordon S, Bettman M, Sutton J, Perez R, Meyer L, McDonnell C, Cole B. Docetaxel/Gemcitabine followed by Gemcitabine and Radiotherapy in Patients with Pancreatic Carcinoma. Am Soc Clin Onc, 2003.
28. Siegel A, Alvarado M, **Barth RJ**, Brady M, Lewis J. Can parathyroid hormone level predict the outcome of parathyroid scintigraphy?. Am Roentgen Ray Society meeting 2004.

29. Pipas, J.M., **Barth RJ**, Zaki B, Colacchio T, Gordon S, Bettman M, Sutton J, Perez R, Meyer L, McDonnell C, Cole B. Docetaxel/Gemcitabine followed by Gemcitabine and Radiotherapy in Patients with Pancreatic Carcinoma. Am Soc Clin Onc, 2004.
30. **Barth RJ**, Wallace P, Fischer D, Smith, J, Noelle R. Treatment of metastatic colorectal patients with a tumor lysate pulsed dendritic cell vaccine: a randomized evaluation of ex vivo CD40L activation. International Society for the Biological Therapy of Cancer, 2004.
31. Valsdottir, E and **Barth RJ**. Induction of humoral immune responses in colorectal cancer patients with a dendritic cell vaccine. American Society of Colorectal Surgeons, 2005.
32. Greer S and **Barth RJ**. Neoadjuvant therapy and local recurrence in pancreatic carcinoma. New England Surgical Society, 2005.
33. Valsdottir, E, Sorensen M, Butterly L and **Barth RJ**. Barriers to screening for colorectal cancer, The Icelandic Medical Journal, 4/2007.
34. Gorechlad J, McCabe E, Higgins J, Likosky D, Lewis P, Rosenkranz K and **Barth RJ**. Screening for recurrences In patients treated with breast conserving surgery: Is there a role for MRI?, New England Surgical Society, 2007.
35. Edmunds H, Szafranska A, Gordon S, Doleshal M, Barth R, Gutman E, Suriawinata A, Korc M, Labourier E, Tsongalis G. Analysis of pancreatic microRNA biomarker candidates In fine needle aspirates preserved In *RNA*Retain** . Association for Molecular Pathology, 2007.